Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2024-01-16 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于科兴生物制药股份有限公司2024年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of the 2024 first extraordinary general meeting (临时股东大会) of the company. It details the legal compliance of the meeting's call, attendance, and voting process, and confirms the validity of the resolutions passed. It does not contain financial statements or management discussion but focuses on the legal aspects of the shareholder meeting and the voting results. This matches the category of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is 3086 characters, relatively short, but it contains detailed voting results and legal opinion on the meeting, not just an announcement of a report publication. Therefore, the best classification is DVA with high confidence.
2024-01-16 Chinese
2024年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2024 First Extraordinary General Meeting" of 科兴生物制药股份有限公司. It includes detailed meeting instructions, agenda, and proposals to be voted on, such as the reappointment of the 2023 audit firm and the election of a non-independent director. The content is typical of materials prepared and distributed for a shareholders' meeting, providing information to shareholders to facilitate discussion and voting. It is not a report itself but rather the presentation and materials for the meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length and detail support this classification with high confidence.
2024-01-08 Chinese
关于签署日常关联交易协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a routine related-party transaction agreement by the company. It details the nature of the transaction, parties involved, pricing, approval procedures, and opinions from independent directors and the sponsor institution. The document does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a related-party transaction, not a financial report or earnings release. The document length is 3606 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-29 Chinese
关于使用部分闲置募集资金和自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company regarding the use of idle raised funds and own funds for cash management. It details the board meeting resolutions, investment purposes, types of investment products, investment limits, risk control measures, and opinions from independent directors, the supervisory board, and the sponsor institution. The document does not contain financial statements or detailed financial results but is a formal disclosure about financing and capital management activities. It is not a full financial report, audit report, or earnings release. The content fits the category of Capital/Financing Update (CAP) as it relates to the company's management of capital and funds.
2023-12-29 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司使用部分闲置募集资金和自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from the sponsor institution (中信建投证券股份有限公司) regarding the use of idle raised funds and own funds by 科兴生物制药股份有限公司 for cash management. It includes regulatory references, approval details, investment purpose, risk control measures, and opinions from the board, independent directors, and supervisors. The document is not a financial report like an annual or interim report, nor is it a brief announcement or a certification letter. It is a formal audit or verification opinion related to the use of funds, which fits the definition of an Audit Report / Information (AR). The document length is 3330 characters, which is relatively short but contains substantive content and detailed verification opinions, not just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2023-12-29 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司2024年度对外担保额度预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信建投证券股份有限公司) regarding the anticipated external guarantee limit for the year 2024 for 科兴生物制药股份有限公司. It includes specifics about the guarantee amount, the decision-making process, the guaranteed subsidiaries, financial data of the subsidiary, and the internal approval procedures. The document is not a full financial report but rather a regulatory or compliance-related verification and opinion statement related to financing guarantees. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not an announcement of a report publication but a formal verification opinion. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related filing that does not fit other categories like Capital/Financing Update (CAP) because it is not announcing new financing but verifying guarantee limits, nor is it an Audit Report or Annual Report. Therefore, the classification is Regulatory Filings (RNS).
2023-12-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.